Reviva Pharmaceuticals Holdings, Inc. announced a public offering with institutional investors for 27,000,000 shares of common stock at $0.335 per share, raising approximately $9 million. The Series E and Series F warrants will have an exercise price of $0.335 per share, with expiration dates of five years and 12 months from the issuance date, respectively. The closing of the offering is expected on September 22, 2025. The net proceeds will fund research, development activities, and general corporate purposes. A.G.P./Alliance Global Partners is the sole placement agent for the offering.

Reviva is a biopharmaceutical company developing therapies for CNS, inflammatory, and cardiometabolic diseases with two drug candidates in the pipeline. The company holds composition of matter patents for these candidates in multiple countries. Forward-looking statements caution investors about risks associated with the offering and the company’s business. For more information, refer to the final prospectus supplement and related SEC filings. Reviva reminds investors not to place undue reliance on forward-looking statements as they are subject to change.

Read more at GlobeNewswire: Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of